New Molecule Shows Promise for Treating Aggressive Triple-Negative Breast Cancer

A newly designed molecule, SU212, is showing promise in the fight against triple-negative breast cancer, one of the most aggressive and challenging forms of the disease to treat. Researchers at Oregon Health & Science University (OHSU) have discovered that this experimental compound can halt the growth and spread of cancer cells in laboratory models, offering a potential breakthrough for patients with limited treatment options. The findings, published in the journal Cell Reports Medicine, center on the molecule’s ability to disrupt a key enzyme that fuels cancer progression.

Understanding Triple-Negative Breast Cancer

Triple-negative breast cancer receives its name from the absence of three common receptors – estrogen, progesterone, and HER2 – found on other types of breast cancer cells. These receptors are often targets for hormone therapy or HER2-directed therapies. Without them, treatment options are significantly reduced, typically relying on chemotherapy, which can have substantial side effects. Approximately 15% of all breast cancers are classified as triple-negative, and the disease disproportionately affects younger women and those with a BRCA1 gene mutation. The American Cancer Society provides further information on this aggressive form of the disease.

How SU212 Works: Targeting ENO1

The research team focused on an enzyme called enolase 1, or ENO1. Cancer cells, in their rapid growth, often exhibit increased levels of ENO1, which plays a crucial role in glycolysis – the process of converting glucose into energy. SU212 works by binding to ENO1, triggering its degradation and effectively cutting off a vital energy supply to the cancer cells. In tests using a humanized mouse model – a model engineered to closely mimic human disease – SU212 not only slowed tumor growth but also reduced metastasis, the spread of cancer to other parts of the body.

“It’s an important step forward to treat triple-negative breast cancer,” explained Dr. Sanjay V. Malhotra, senior author of the study and co-director of the Center for Experimental Therapeutics at the OHSU Knight Cancer Institute. “Triple-negative breast cancer is an aggressive form of cancer and there are no effective drugs available right now.”

Beyond Breast Cancer: Potential for Wider Application

The implications of this discovery extend beyond triple-negative breast cancer. Researchers believe that targeting ENO1 could be effective against other cancers that also rely heavily on glycolysis, including glioma (a type of brain cancer), pancreatic cancer, and thyroid carcinoma. The study published in Cell Reports Medicine details the mechanism of action and the promising results observed in the mouse models.

A Favorable Safety Profile and Metabolic Considerations

Unlike some other glycolytic enzyme inhibitors, SU212 has demonstrated a favorable safety profile in initial testing, with minimal toxicity and no apparent interference with essential biological systems. This is particularly noteworthy, as disrupting metabolic pathways can sometimes lead to unintended consequences. Dr. Malhotra also pointed out that the mechanism of action may be especially relevant for patients with metabolic disorders like diabetes, where glucose metabolism is already compromised. The molecule even showed promise in improving fatty liver conditions and lowering blood glucose levels in a diabetic mouse model.

From Lab to Clinic: The Road Ahead

While these findings are encouraging, it’s crucial to remember that the research is still in its early stages. The next step is to advance SU212 toward human clinical trials. This process is complex and requires substantial investment to secure Food and Drug Administration (FDA) approval and conduct rigorous studies involving patients. OHSU News provides details on the next steps in the development process.

The Importance of Humanized Mouse Models

The use of a humanized mouse model was critical to the success of this research. These models are engineered to have a human immune system and other human characteristics, making them a more accurate representation of human disease than traditional mouse models. This increases the likelihood that findings observed in the mice will translate to humans.

Funding and Collaboration

The research was supported by grants from the National Cancer Institute, the National Institute of Aging, the National Heart, Lung, and Blood Institute, the Department of Defense, the Knight Cancer Institute, and the Biomedical Innovation Program at OHSU, as well as Sheila Edwards-Lienhart endowment funds. This collaborative effort highlights the importance of sustained funding for cancer research.

What’s Next for SU212?

The OHSU team is actively working to secure the necessary funding and regulatory approvals to initiate clinical trials. The timeline for these trials is currently uncertain, but researchers are optimistic that SU212 could eventually become a valuable new treatment option for patients with triple-negative breast cancer and potentially other cancers as well. Further research will also focus on identifying biomarkers that can predict which patients are most likely to respond to SU212, allowing for a more personalized approach to treatment. ScienceDaily offers a concise overview of the discovery and its potential impact.